Combined treatment of patients with locally advanced rectal cancer

The objective of this study was to improve the immediate and long-term results of combined treatment of patients with locally advanced rectal cancer. The study included 128 patients with morphologically confirmed diagnosis and clinical stage cT3/T4 and N-/N+, treated from 1998 to 2009. The compariso...

Full description

Saved in:

Bibliographic Details
Published in:	Voprosy onkologij Vol. 60; no. 4; p. 497
Main Authors:	Berdov, B A, Erygin, D V, Nevol'skikh, A A, Titova, L N, Zamulaeva, I A, Kondrashova, L M
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) 2014
Subjects:	Adenocarcinoma - pathology Adenocarcinoma - surgery Adenocarcinoma - therapy Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemoradiotherapy, Adjuvant Drug Administration Schedule Female Fluorouracil - administration & dosage Follow-Up Studies Humans Infusions, Intravenous Male Middle Aged Neoadjuvant Therapy - adverse effects Neoadjuvant Therapy - methods Neoplasm Staging Rectal Neoplasms - pathology Rectal Neoplasms - surgery Rectal Neoplasms - therapy Survival Analysis Time Factors Treatment Outcome
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The objective of this study was to improve the immediate and long-term results of combined treatment of patients with locally advanced rectal cancer. The study included 128 patients with morphologically confirmed diagnosis and clinical stage cT3/T4 and N-/N+, treated from 1998 to 2009. The comparison group had 64 patients, combined treatment included prolonged preoperative radiotherapy 4 Gy and 40 Gy, surgery was performed after 4 weeks. In the study group--also 64 patients--combined treatment consisted of preoperative chemoradiotherapy (continuous a-120 hour infusion of 5-fluorouracil at a dose of 500 mg/m2 in the first and last week of radiotherapy in 2 Gy to 50 Gy), surgery was performed through 6 weeks after chemoradiotherapy. Excision of the primary tumor was performed in 40 (62.5%) patients in the control group and in 53 (82.8%) patients in the study group. Wherein R-0 resections were performed in 32 (67%) patients and in 41 (73%), and R-1 resections--in 1 (2%) patients, and 7 (13%) patients in the control and study groups respectively. A 5-year survival rate was 43.6 ± 7.2% control and 62.7 ± 5.1 % in the study group.
ISSN:	0507-3758